22 August 2018 | News
The launch approval is helpful for Genetron Health to enhance development and innovation for tumor liquid biopsy, and provide support for the healthy development of the oncogene detection industry
At the end of 2017, Chongqing Food and Drug Administration of China Food and Drug Administration (CFDA) officially approved GENETRON 3D, the biochip reader of Genetron Health, to launch.
Currently, many domestic hospitals and scientific research institutions have purchased the reader for the development and scientific research of oncogene detection reagent.
The GENETRON 3D biochip reader can clearly process and analyze data of special digital PCR chip which has completed the PCR amplified reaction and without the limitation of matched kit.
Both human EGFR gene T790M mutation test kit under application and registration and similar detection kit under development by Genetron Health can be used together with this reader.
The reader can be applied in medical institutions, clinical laboratories and scientific research institutions, etc. to further effectively improve the detection scope, quality and speed.
Except for the detection of matched tumor liquid biopsy ctDNA, it can also be used for the analysis of viral load, detection of low content pathogen, prenatal screening and diagnosis, analysis of gene expression, verification of the 2nd generation of sequencing result and analysis of methylation level.
Based on the biochip reader, Genetron Health develops detection solutions against various cancers and sample types, in order to expand its application ranges. Especially in the liquid biopsy field, the detection against over 50 gene loci of lung cancer, breast cancer, colorectal cancer, stomach cancer and other cancers have been developed.
The launch approval is helpful for Genetron Health to enhance development and innovation for tumor liquid biopsy, and provide support for the healthy development of the oncogene detection industry.
Genetron Health gives full play to the powerful strength of digital PCR technology, focuses on development and application of world leading liquid biopsy, continuously reforms and progresses, leads breakthrough innovations of oncogene detection industry with practical actions, and powerfully promotes the rapid development of precision medicine in China.